|
gptkbp:instanceOf
|
gptkb:drug
orexin receptor antagonist
|
|
gptkbp:abusePotential
|
low
|
|
gptkbp:approvalYear
|
2014
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
N05CM17
|
|
gptkbp:bioavailability
|
82%
|
|
gptkbp:blackBoxWarning
|
no
|
|
gptkbp:brand
|
gptkb:Belsomra
|
|
gptkbp:CASNumber
|
1030377-33-3
|
|
gptkbp:category
|
sleep aid
sedative
hypnotic
|
|
gptkbp:chemicalClass
|
diarylurea
|
|
gptkbp:contraindication
|
narcolepsy
|
|
gptkbp:controlledSubstanceSchedule
|
Schedule IV (US)
|
|
gptkbp:developedBy
|
gptkb:Merck_&_Co.
|
|
gptkbp:eliminationHalfLife
|
12 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:firstBook
|
yes
|
|
gptkbp:form
|
gptkb:tablet
|
|
gptkbp:hasMolecularFormula
|
C23H23ClN6O2
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Suvorexant
|
|
gptkbp:KEGGID
|
D10368
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:maximumDose
|
20 mg/day
|
|
gptkbp:mechanismOfAction
|
orexin receptor antagonist
|
|
gptkbp:metabolism
|
liver (CYP3A, CYP2C19)
|
|
gptkbp:pregnancyCategory
|
C (US)
B3 (Australia)
|
|
gptkbp:prescriptionStatus
|
Rx-only (US)
|
|
gptkbp:proteinBinding
|
99%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL2105757
28536936
DB09025
46215922
|
|
gptkbp:riskOfDependence
|
low
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
fatigue
headache
hallucinations
somnolence
sleep paralysis
abnormal dreams
|
|
gptkbp:synonym
|
gptkb:Belsomra
MK-4305
|
|
gptkbp:UNII
|
7X9R1UM73A
|
|
gptkbp:usedFor
|
insomnia
|
|
gptkbp:bfsParent
|
gptkb:347396-82-1
|
|
gptkbp:bfsLayer
|
6
|